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Abstract: New potential tumor markers such as matrix metalloproteinases and their inhibitors have been extensively stud-
ied during the last decades. The aim is to ﬁ  nd prognostic markers that are measurable in easily available samples, such as 
serum or plasma. The proper sample type to use when measuring the levels of gelatinases and their inhibitors from blood 
samples is currently under critical evaluation. In this study, the effect of sample type is studied in 26 healthy controls, and 
the result is conﬁ  rmed in a series of 80 breast carcinoma patients.
Sample type had the most evident effect on the levels of TIMP-1 and MMP-9. Serum samples gave about two-fold levels 
of TIMP-1 compared to plasma samples (p < 0.001), with a strong linear correlation between these two (r = 0.79). Pro-MMP-9 
levels were signiﬁ  cantly affected by the presence of a blood coagulation activator in the serum sample, or a different anti-
coagulant in the plasma sample. The serum and plasma values had only a weak correlation (r = 0.37). 
In conclusion, sample type should be carefully considered, especially when measuring proMMP-9, and plasma should be 
preferred for this measurement. For TIMP-1 the correlation of serum and plasma values is good; the use of serum samples 
can therefore be justiﬁ  ed as long as the generally higher levels in the serum are acknowledged.
Keywords: preanalytical aspects, ELISA, gelatinases, tissue inhibitor of metalloproteinases.
Introduction
Matrix metalloproteinases (MMPs) form an enzyme family of zinc-dependent, structurally related 
enzymes that modify the extracellular matrix and regulate its turnover. Moreover, MMPs and their 
naturally occurring inhibitors, TIMPs, take part in complex signaling cascades affecting cell growth, 
tissue differentiation, angiogenesis and apoptosis. Abnormalities in these cascades cause distraction in 
normal functioning of the cells and tissues, leading further to diseases and even malignant transforma-
tions. Currently, a role for these enzymes has been suggested in several physiological processes requiring 
ECM remodeling, such as fetal differentiation of tissues and wound healing. In addition, these enzymes 
have been studied in a variety of pathological conditions including cardiovascular diseases, rheumatic 
diseases, and malignancies (reviewed in Sternlicht and Werb, 2001; Turpeenniemi-Hujanen, 2005). The 
tumor tissue expression of the gelatinases MMP-2 and -9 has been shown to correlate with poor prog-
nosis in several malignancies (Turpeenniemi-Hujanen, 2005). Some recent studies suggest that tissue 
inhibitor of metalloproteinases-1 (TIMP-1) and gelatinase B (MMP-9) could be utilized as novel tumor 
markers in the determination of prognosis in the carcinomas of head and neck, breast, ovary, and colon 
(Holten-Andersen et al. 2000; Ranuncolo et al. 2003; Talvensaari-Mattila et al. 2005a; Talvensaari-
Mattila et al. 2005b; Rauvala et al. 2005; Ruokolainen et al. 2005a; Ruokolainen et al. 2005b). In these 
studies, TIMP-1 and MMP-9 levels are measured from circulating blood; however, the sample type 
used varies. Since MMPs and TIMPs have inﬂ  uence in several normal processes, the physiological and 
preanalytical factors affecting these enzyme levels should be carefully identiﬁ  ed in order to use these 
enzymes as tumor biomarkers. Platelets physiologically contain MMP-9 and TIMP-1, and the use of 
serum has therefore been questioned in tumor marker studies (Jung et al. 2001; Jung, 2005). However, 
other factors such as coagulation accelerators or anticoagulants could also have an effect on these 
enzyme levels. 
Please note that this article may not be used for commercial purposes. For further information please refer to the copyright 
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The aims of this study were ﬁ  rstly, to determine 
whether the sample type (serum or plasma) used 
affects the levels of gelatinases and their inhibitors 
measured in blood. This experiment was done on 26 
healthy volunteers using 4 different sample types. 
Secondly, the differences between serum and plasma 
levels of metalloproteinases and their inhibitors were 
studied in the preoperative blood of 80 breast cancer 
patients in order to verify that the observations on 
sample type apply to patient material. Thirdly, the 
levels of gelatinases and their inhibitors in the blood 
of healthy controls and patients were compared. 
Materials and Methods
Study design and sample collection
The material consisted of blood samples from 80 
patients diagnosed with primary breast cancer in 
Oulu University hospital during March 2003–
March 2004, and 26 healthy controls volunteering 
for the project. All patients and controls in this 
study have received and signed an informed 
consent, where they give permission to use their 
blood samples for research purposes. 
Healthy controls gave 2 different serum and 2 
different plasma samples. The serum samples from 
each volunteer were collected into one glass tube 
(367608) that contained no artiﬁ  cial coagulation 
activator, and into another plastic serum tube with 
silicone-coated interior and gel, with added artiﬁ  cial 
coagulation activator, referred to as “serum+” in the 
text (367957). Plasma samples were collected into 
one lithium-heparin plastic tube (367374), and into 
another plastic tube containing K2EDTA (368856). 
Patient samples were collected into one serum tube 
corresponding to serum+, and one EDTA plasma 
tube. All sample tubes were purchased from BD 
Vacutainer systems, Plymouth, U.K. The patient 
samples were collected during March 2003–March 
2004, and control samples during September 2005. 
After collecting, the blood samples were 
allowed to clot thoroughly for 30 minutes before 
centrifugation, centrifuged at 3000 rpm for 10 
minutes, and serum/plasma was aspirated into 
polypropylene micro tubes (Sarstedt, Nurnberg, 
Germany), and stored in a refrigerator at –75 ºC. 
TIMP-1, TIMP-2, proMMP-9, and proMMP-2/
TIMP-2 complex concentrations were determined 
from all samples. In addition, total proMMP-2 and 
active MMP-2 concentrations were determined 
from 20 control samples. 
The descriptive histopathological and clinical 
data of breast carcinoma patients is summarized 
in Table 3.
ELISA analysis
The enzyme-linked immunosorbent assay (ELISA) 
was used to detect the circulating TIMP-1, TIMP-2, 
proMMP-9, proMMP-2 levels, active MMP-2 
levels, and proMMP2-TIMP2 complex levels from 
serum and plasma samples. TIMP-1, TIMP-2, 
proMMP-9 and proMMP2-TIMP2 complex were 
detected by coating 8-well E.I.A/R.I.A strips for 
microtiter plates (Corning Inc., Corning, NY, 
U.S.A.) with monoclonal antibodies, anti-TIMP-1 
(DB120D1), antiMMP-9 (Ge-213), or anti-TIMP-2 
antibody (for TIMP-2 and proMMP-2/TIMP-2 
complex, clone T2-101). The diluted serum or 
plasma samples were then added, followed by 
polyclonal anti-TIMP-1, anti-TIMP-2 (DB-205), 
anti-MMP-9 (DB-209), or anti-MMP-2 (for 
proMMP-2/TIMP-2 complex, DB-202) as the 
second antibody (all antibodies described in these 
ELISA analyses were purchased from SBA 
Sciences, Oulu, Finland). Anti-chicken horseradish 
peroxidase enzyme (Chemicon International, 
Temecula, CA, U.S.A.) served as the enzyme 
conjugate, and the reaction was visualized by OPD 
(o-phenylenediamine dihydrochloride) enzyme 
substrate (Sigma, Steinheim, Germany). The absor-
bances were read at 492 nm wavelength by Anthos 
Reader 2001. 
A commercial assay kit (Human Biotrak Elisa 
system for detecting MMP-2 by Amersham Biosci-
ences, Buckinghamshire, England) was used to 
detect the total and active MMP-2 levels. The assay 
for total proMMP-2 (RPN 2617) recognized both 
free proMMP-2 and proMMP2-TIMP2 complexes, 
whereas the assay used in measuring the active 
MMP-2 (RPN 2631) recognized only free active 
forms of MMP-2. The assay was conducted 
following the manufacturer’s instructions. 
Each sample was run in duplicate in order to 
minimize intra-assay variation. The absorbance 
values for standard samples and the standard curves 
constructed for each assay were compared and used 
to minimize the interassay variation. The sensitivity 
of the assays was 1ng/ml for TIMP-1 and MMP-9, 
and 2 ng/ml for TIMP-2 and the proMMP-2/TIMP-2 
complex. Sensitivities for the total proMMP-2 and 
active MMP-2 were 0.37 ng/ml and 190 pg/ml, 
respectively.Biomarker Insights 2007: 2 119
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Statistical analysis
The distributions of the serum and plasma concen-
trations were ﬁ  rst tested for normality for each 
protein in the group of patients and controls 
separately. Normality of the distribution was deter-
mined by Kolmogorow-Smirnov’s test with Lillefors 
signiﬁ  cance correction. Descriptive statistics (mean, 
median) are given according to normality of the 
distribution. In the control group, one-way ANOVA 
analysis with Scheffe’s test for subset analysis or 
Kruskall-Wallis test were ﬁ  rst used in the analysis 
of 4 different sample types. In the case of signiﬁ  cant 
results, the analyses were continued by pairing the 
variables and analyzing them with Student’s T-test 
or Mann-Whitney’s U-test. T-test and U-test were 
used in analyzing the differences between patients’ 
serum and plasma samples and between patients 
and controls. The linearity of the correlation of 
serum and plasma concentrations was tested with 
Pearson r and linear regression model. P-values < 0.05 
were considered significant. All statistics were 
performed using SPSS software.
Results
Sample type effect in healthy controls
The effect of the sample type used was ﬁ  rst studied 
in the group of twenty-six healthy volunteers. 
Sample type was found to affect both MMP and 
TIMP concentrations. Signiﬁ  cant differences were 
observed in the assays for TIMP-1, proMMP2-
TIMP2 complex, proMMP-9 and active MMP-2. 
For TIMP-1, the plasma levels were signiﬁ  cantly 
lower than the serum levels (p < 0.001, Table 1). 
The subsets of native serum, serum with coagula-
tion activator, LiHe and EDTA plasma were exam-
ined by Scheffe’s test. Coagulation activation in 
the serum samples and the type of anticoagulant 
used in the plasma samples did not affect the 
TIMP-1 levels, resulting in native serum paired 
with serum+, and LiHe plasma paired with EDTA 
plasma as homogeneous subsets (Fig 1A).
ProMMP-9 serum levels were significantly 
affected by coagulation activation, giving the 
median 30.4 ng/ml for native serum and the mean 
124.8 ng/ml for serum+ (p < 0.001, Table 1, 
Fig 1B). ProMMP-9 levels were also signiﬁ  cantly 
affected by anticoagulant type, with lower MMP-9 
levels for LiHe plasma than for EDTA plasma 
(p < 0.001, Fig 1B). Subsets of different sample 
types were then paired for comparison, and studied 
by T-test or U-test. The proMMP-9 levels in the 
lithium- heparin plasma, and serum samples with 
coagulation activator (serum+) differed signiﬁ  -
cantly from all other sample types, giving p < 0.001 
in all subgroup analyses of 2 variables (Fig 1B, 
data not shown). When EDTA plasma and native 
serum were paired for comparison, no signiﬁ  cant 
differences in the proMMP-9 levels were found in 
the U-test (p = 0.06, Fig 1B, data not shown). 
For the proMMP2-TIMP2 complex, the protein 
concentrations in the EDTA plasma were lower 
than in other sample types (p < 0.001, Table 1). 
For active MMP-2, LiHe plasma levels were 
signiﬁ  cantly lower than the corresponding serum 
levels (Table 1). The coagulation activator did not 
have any effect on the serum levels for active 
MMP-2 and the proMMP2-TIMP2 complex. For 
TIMP-2 and proMMP-2, no signiﬁ  cant differences 
were found between the sample types (Table 1).
Effect of sample type in breast cancer 
patients
Similar effects caused by sample type were 
discovered when blood samples of 80 breast 
cancer patients were analyzed. For these samples, 
the levels of TIMP-1, proMMP-9, proMMP2-
TIMP2 complex and TIMP-2 were compared in 
serum with coagulation activator (serum+) and 
in EDTA plasma. TIMP-1 levels were signiﬁ  -
cantly lower in plasma (median 237.8 ng/ml) than 
in serum (median 408.4 ng/ml) (p < 0.001, Table 2). 
Although the levels were different, the ranges 
were overlapping and there was a strong linear 
correlation between plasma and serum concentra-
tions with Pearson r = 0.79 and R-squared 0.61, 
the linear regression analysis model of plasma 
TIMP-1 explaining 61% of the total variation of 
serum TIMP-1 values (Table 2, Fig 2A). For the 
proMMP2-TIMP2 complex, the levels were 
signiﬁ  cantly lower in EDTA plasma (median 
960.9 ng/ml) than in serum (mean 1296.9 ng/ml) 
samples (p < 0.001, Table 2). Despite the 
differences in the mean/median levels, there was 
a strong linear correlation between plasma and 
serum values with Pearson r = 0.89 and R-squared 
0.79 (Table 2, Fig 2C). ProMMP-9 concentrations 
were found to be signiﬁ  cantly lower in plasma 
samples than in serum+ samples (p < 0.001, 
Table 2). There was a weak linear correlation 
between plasma and serum concentrations, but the 
linear regression model of plasma TIMP-1 explained Biomarker Insights 2007: 2 120
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only 13% of the total variation of serum TIMP-1 
values (Table 2, Fig 2B). For TIMP-2 no differences 
were found between plasma and serum samples, and 
there was a strong linear correlation between serum 
and plasma TIMP-2, the linear regression model 
explaining 53% of the total variation of serum 
TIMP-2 values (Table 2, Fig 2D).
Differences between patients 
and controls
The ranges for TIMP-1 concentrations were wider in 
both plasma and serum samples of breast cancer 
patients compared with healthy controls (Fig 3A), 
although there were no signiﬁ  cant differences between 
patients and controls for TIMP-1 in plasma or serum. 
ProMMP-9 concentrations in both plasma (p = 0.002) 
and serum (p < 0.001) were signiﬁ  cantly lower in the 
blood of breast cancer patients than in control samples 
(Fig 3B). The protein concentrations in both plasma 
(p < 0.001) and serum (p < 0.001) were also lower for 
TIMP-2 in patient samples compared with controls 
(data not shown). For the proMMP-2/TIMP-2 
complex no significant differences were found 
between patients and controls (data not shown). 
Discussion
In this study, sample type was found to have an 
effect on the concentrations of metalloproteinases 
and their inhibitors in circulating blood. Sample 
type had the clearest effect on the levels of 
proMMP-9 and TIMP-1. Platelets contain both 
MMP-9 and TIMP-1, and it has been shown that 
platelet aggregation during clotting can lead to 
increased release of MMP-9 and TIMP-1 (Holten-
Andersen et al. 2002; Sheu et al. 2004). 
Recent studies suggest that TIMP-1 has prog-
nostic value in head and neck SCC (Ruokolainen 
et al. 2005a), colorectal carcinoma (Holten-
Table 1. Protein concentrations according to sample type in healthy controls.
Protein  Sample type *  Mean/median   Range  Signiﬁ  cance
   (ng/ml)  (ng/ml) 
TIMP-1      
 Native  serum  462.7  288.9–754.6 
 Serum  +    486.5  340.1–680.3 
 LiHe  259.7  163.7–344.0 
  EDTA  243.9  147.9–395.1  p < 0.001
TIMP-2      
 Native  serum  201.8  144.0–311.1 
 Serum  +  197.7  167.1–317.2 
 LiHe  187.2  125.6–347.3 
 EDTA  199.8  141.1–307.1  N.  S
MMP2-TIMP2      
 Native  serum  1456.4  749.8–2168.7 
 Serum  +  1436.7  805.2–2087.7 
 LiHe  1384.2  854.8–2198.3 
  EDTA  1119.1  641.6–1780.6  p < 0.001
ProMMP-9      
 Native  serum  30.4  10.7–107.3 
 Serum  +  124.8  51.4–410.9 
 LiHe  7.3  3.8–40.6 
  EDTA  24.3  5.5–66.5  p < 0.001
ProMMP-2      
 Native  serum  1259.9  793.9–1881.9 
 Serum  +  1197.3  777.3–1790.3 
 LiHe  1224.7  783.0–1894.2 
 EDTA  1195.5  770.6–1791.2  N.  S
Active MMP-2       
 Native  serum  29.4  10.8–68.1 
 Serum  +  33.5  10.0–78.7 
  LiHe  8.51  5.67–14.7  p < 0.001
* Serum + indicating serum with coagulation activator.Biomarker Insights 2007: 2 121
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Figure 1. Protein concentrations according to sample type for A) TIMP-1, B) proMMP-9 in healthy controls (n = 26).Biomarker Insights 2007: 2 122
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Table 2. Protein concentrations according to sample type in breast carcinoma patients.
Protein  Sample type  Mean/median  Range  p-value*  Pearson r  R-squared
   (ng/ml)  (ng/ml)
TIMP-1          
 Serum  +  408.4  118.6–842.5    
  EDTA   237.8  139.8–669.0  p < 0.001  0.79  0.61
TIMP-2          
 Serum  +  170.4  100.5–293.8    
 EDTA    170.8  115.6–259.8  N.S.  0.73  0.53
MMP2-          
TIMP-2 Serum  +  1296.9  743.0–2616.4     
 EDTA  960.9  662.7–1975.2  p  <  0.001  0.89  0.79
MMP-9          
 Serum  +  63.3  13.3–216.4    
  EDTA   11.8  4.0–106.2  p < 0.001  0.37  0.13
*Signiﬁ  cance of the sample type effect (plasma/serum).
Andersen et al. 2000), ovarian carcinoma (Rauvala 
et al. 2005) and breast carcinoma (Talvensaari-
Mattila et al. 2005a). Some of these results are based 
on serum (Talvensaari-Mattila et al. 2005a; Ruoko-
lainen et al. 2005a; Rauvala et al. 2005) and some 
on plasma samples (Holten-Andersen et al. 2000). 
The use of serum has been questioned because of 
the generally higher levels of serum TIMP-1 in 
comparison with plasma TIMP-1 (Jung et al. 2005). 
In an experiment by Jung et al. (2005), up to 5–7 
times higher concentrations of TIMP-1 were shown 
in serum versus plasma. The blood samples in this 
experiment were collected into serum tubes that 
contained artiﬁ  cial coagulation activators. However, 
in our experiment the levels of TIMP-1 in the serum 
were about 2-fold higher than in the plasma in 
patients and in controls, and were not affected by 
coagulation activators or anticoagulants. In addition, 
a strong correlation existed between TIMP-1 in 
serum and plasma samples. Patients and controls 
did not have signiﬁ  cant differences in their serum 
or plasma TIMP-1 levels, although the ranges for 
serum and plasma TIMP-1 were wider in patients 
in comparison with controls. This could indicate the 
presence of a disturbance, such as cancer, that could 
affect the levels of the analytes.
Most studies on the effect of preanalytical condi-
tions on metalloproteinase concentrations in the 
blood concern the analysis of proMMP-9. It has 
been shown in several studies that serum has gener-
ally higher levels of MMP-9 than do plasma 
samples. This has been documented using both 
ELISA and gelatin zymography (Jung, 2005; Jung 
et al. 2001; Gerlach et al. 2005; Makowski et al. 
2003; Mannello, 2003a; Mannello et al. 2003b). In 
our experiment it was evident that coagulation acti-
vators had an effect on the proMMP-9 serum levels, 
giving up to 4-fold MMP-9 levels in comparison 
with native serum, probably due to platelet release 
of MMP-9. A similar observation was made by Jung 
et al. (2001). However, it is notable that in the 
experiment by Jung et al. (2001) the native serum 
with no coagulation activator had markedly higher 
MMP-9 levels than what was measured in plasma. 
In our experiment, the native serum concentrations 
of MMP-9 were found to resemble those measured 
in EDTA plasma. Anticoagulant type also had a 
signiﬁ  cant effect, giving LiHe plasma signiﬁ  cantly 
lower concentrations of MMP-9.
The use of proper sample type in measuring 
MMP-9 from blood is discussed in many studies, 
and some show that citrate plasma might be the 
safest option (Mannello, 2003a; Mannello et al. 
2003b), suggesting that serum should not be used 
at all in these measurements. However, in recent 
studies done on serum, using material collected 
into native serum tubes, proMMP-9 has been 
shown to have prognostic value in breast carcinoma 
and head and neck SCC (Talvensaari-Mattila et al. 
2005b; Ruokolainen et al. 2005b). In the study by 
Talvensaari-Mattila et al. (2005b), low preopera-
tive serum proMMP-9 was found to correlate with 
poor relapse-free survival. In our current study, 
breast cancer patients were found to have lower 
serum and plasma proMMP-9 concentrations than 
healthy controls, the difference being even clearer 
in serum samples. This might suggest that higher 
serum proMMP-9 could not only be due to artefact 
caused by platelet release of MMP-9, but that 
MMP-9 measured in the serum actually relates to Biomarker Insights 2007: 2 123
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Figure 2. Linear regression models for serum A) TIMP-1, B) MMP-9, C) proMMP2-TIMP2 complex, D) TIMP-2 in breast cancer patient 
material.Biomarker Insights 2007: 2 124
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Figure 3. Corresponding protein concentrations according to sample type for A) TIMP-1 and B) proMMP-9 in breast carcinoma patients and 
healthy controls.Biomarker Insights 2007: 2 126
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Table 3. Clinico-pathological parameters and patient characteristics of breast carcinoma patients.
Tumor parameter  n  % of   Patient   n  % of   median  
   patients  characteristics    patients  (range)
Histological type      Menopausal     
ductal 57  71.3  status     
lobular 13  16.3  pre  26  35.1 
DC in situ  4  5.0  post  48  64.9 
tubular 3  3.8  Surgery     
papillar 1  1.3  mastectomy  38  47.5 
mucinous 1  1.3  breast     
Size of the tumor      conserving  42  52.5 
<2cm 51  66.2  Chemotherapy     
2–5cm 24  31.2  yes  31  38.8 
>5cm 2  2.6  no  49  61.3 
Nodal status      Radiotherapy     
negative 50  62.5  yes  70  87.5 
≤2 positive nodes  19  23.8  no  10  12.5 
>2 positive nodes  11  13.8  Endocrine     
Stage*     therapy     
1 36  47.4  yes  30  37.5 
2A 23  30.3  no  50  62.5 
2B  16  21.5  Age at diagnosis      56
3A 1  1.3        (28–87)
Histological grade**           
1 9  12.3       
2 35  47.9       
3 29  39.7       
Hormone receptor 
status          
ER positive  61  81.3       
ER negative  14  18.7       
PR positive  45  60.0       
PR negative  30  40.0       
*according to UICC TNM classiﬁ  cation.
disease progression. Therefore, proMMP-9 
measurements done on serum could still have some 
value, even though caution should be maintained 
in interpreting the results. It is notable that the 
plasma proMMP-9 concentration could only 
explain 13% of the total variation in the serum 
proMMP-9 values in this study (when a coagula-
tion activator was present), and the use of plasma 
samples is therefore probably a safer option to 
produce reliable results.
The blood samples of breast carcinoma patients 
were exposed to a longer storage time than control 
samples in this study. It has been shown by Rouy 
et al. (2005) that detectable levels of proMMP-9 
decrease heavily in citrate plasma samples over 
time. Therefore we cannot exclude that the higher 
levels of control samples might be partly due to 
enzyme degradation in this study. The effect 
appears to be speciﬁ  c for proMMP-9, since no such 
differences were found for proMMP-2 or TIMP-1 
(Rouy et al. 2005). Since proMMP-9 is sensitive 
for several (coagulation activators, anticoagulants, 
storage time) preanalytical issues, standardization 
is crucial if this enzyme is to be measured from 
circulation. 
For the proMMP2-TIMP2 complex the use of 
EDTA plasma as a sample gave lower concentra-
tions than did other sample types. It has previously 
been suggested that the use of EDTA in blood 
samples might alter the measured MMP levels, 
since EDTA is able to chelate Zn2
+, possibly 
leading to lower measured proMMP-2 levels 
(Imafuku et al. 2002), and in some studies (Jung 
et al. 1998; Mannello et al. 2003b) lower levels of 
proMMP-2 immunoreactive protein have been 
observed in EDTA plasma. It has been shown that 
during aggregation, platelets release MMP-2 in its 
latent form (Sawicki et al. 1997) as well as other 
components of the proMMP2/MT1-MMP/TIMP-2 
system (Kazes et al. 2000). However, we did not Biomarker Insights 2007: 2 127
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observe differences in the total proMMP-2 concen-
trations between different sample types, but when 
measuring active MMP-2 the LiHe plasma gave a 
lower concentration than serum samples, suggesting 
platelet release of MMP-2.
In a study by Jung et al. (1998), high concentra-
tions of TIMP-2 were also found in heparin plasma 
in comparison with EDTA plasma and serum. In 
the current study no such differences were found. 
Instead, we found surprisingly that breast cancer 
patients had signiﬁ  cantly lower TIMP-2 levels than 
did healthy controls. In breast carcinoma, no 
evidence currently exists that TIMP-2 could be 
prognostic when measured in peripheral blood. 
However, the presence of the disease might alter 
the balance of the proteolysis. Low TIMP-2 levels 
in the blood of breast carcinoma patients could 
indicate more activated MMP-2 and therefore 
higher usage of TIMP-2, or alternatively, the lower 
levels could be due to lower production of TIMP-2, 
leading to lesser inhibition of MMP-2 activity.
Taken together, blood sample type used was 
found to have a signiﬁ  cant effect on metallopro-
teinases and their inhibitor levels. The results on 
the sample type effect obtained using healthy 
controls were reproducible in patient material, 
although the levels of the studied enzymes showed 
some differences between patients and controls.
The blood sample type had the clearest effect 
when measuring MMP-9 or TIMP-1. MMP-9 
levels are affected by coagulation activation and 
the anticoagulant used, and MMP-9 is therefore 
more safely determinable in plasma samples. 
TIMP-1 gives higher serum than plasma levels, 
but the correlation between these values is very 
good. Serum might be a valid sample choice for 
measuring TIMP-1 as long as the generally higher 
levels are acknowledged. 
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